Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in RET-rearranged NSCLC
NCT01823068Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Nov 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vandetanib in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Started Nov 2014; status: completed.
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01823068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01823068.